Quick Answer
Eton Pharmaceuticals, Inc. reported Cash and Equivalents of $25.94 million for fiscal year 2025.
Eton Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $25.94M | +73.7% |
| 2024 | $14.94M | -30.2% |
| 2023 | $21.39M | +31.2% |
| 2022 | $16.30M | +13.2% |
| 2021 | $14.41M | -32.4% |
| 2020 | $21.30M | +76.5% |
| 2019 | $12.07M | -54.9% |
| 2018 | $26.73M | +103.2% |
| 2017 | $13.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.12M | +83.2% | +46.3% |
| June 30, 2025 | $25.38M | +43.4% | +45.7% |
| March 31, 2025 | $17.42M | +4.6% | +16.6% |
| December 31, 2024 | $14.94M | -30.2% | -26.3% |
| September 30, 2024 | $20.26M | -8.2% | +14.5% |
| June 30, 2024 | $17.69M | -18.0% | +6.2% |
| March 31, 2024 | $16.66M | +13.2% | -22.1% |
| December 31, 2023 | $21.39M | +31.2% | -3.1% |
- Eton Pharmaceuticals, Inc. showed an increase of +73.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Eton Pharmaceuticals, Inc.’s cash and equivalents has grown by 97.2% (from $13.16 million to $25.94 million).
- The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: